Nationwide Fund Advisors Has $1,683,000 Stake in AngioDynamics Inc. (ANGO)
Nationwide Fund Advisors boosted its position in AngioDynamics Inc. (NASDAQ:ANGO) by 0.4% during the second quarter, Holdings Channel reports. The firm owned 117,097 shares of the company’s stock after buying an additional 430 shares during the period. Nationwide Fund Advisors owned about 0.32% of AngioDynamics worth $1,683,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently modified their holdings of ANGO. BNP Paribas Arbitrage SA increased its position in shares of AngioDynamics by 99.2% in the second quarter. BNP Paribas Arbitrage SA now owns 8,174 shares of the company’s stock worth $117,000 after buying an additional 4,071 shares during the period. Bank of Montreal Can bought a new stake in AngioDynamics during the second quarter worth approximately $201,000. Emerald Acquisition Ltd. bought a new stake in AngioDynamics during the second quarter worth approximately $238,000. Strs Ohio boosted its stake in AngioDynamics by 76.0% in the second quarter. Strs Ohio now owns 22,700 shares of the company’s stock worth $326,000 after buying an additional 9,800 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in AngioDynamics during the first quarter worth approximately $289,000. Institutional investors and hedge funds own 69.12% of the company’s stock.
Shares of AngioDynamics Inc. (NASDAQ:ANGO) traded up 0.23% during mid-day trading on Monday, reaching $17.11. 15,958 shares of the company traded hands. The stock’s 50-day moving average is $16.90 and its 200-day moving average is $14.50. AngioDynamics Inc. has a 52 week low of $9.71 and a 52 week high of $17.64. The company’s market capitalization is $628.60 million.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, October 5th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.04. AngioDynamics had a negative net margin of 11.84% and a positive return on equity of 4.46%. The company had revenue of $88.10 million for the quarter. During the same period in the previous year, the business posted $0.11 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities analysts predict that AngioDynamics Inc. will post $0.66 EPS for the current fiscal year.
ANGO has been the subject of a number of research reports. Zacks Investment Research cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. KeyCorp set a $18.00 target price on shares of AngioDynamics and gave the stock a “buy” rating in a research note on Monday, September 12th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $15.25.
In other news, Director David F. Burgstahler sold 2,250,000 shares of the firm’s stock in a transaction on Friday, August 5th. The shares were sold at an average price of $14.62, for a total value of $32,895,000.00. Following the completion of the sale, the director now owns 23,988 shares in the company, valued at approximately $350,704.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of the firm’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,763,420.00. The disclosure for this sale can be found here. Company insiders own 1.88% of the company’s stock.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.